Buy the dip: The latest mRNA technology is well-positioned to react to new variants should current vaccines and treatments fail. Central bankers are poised to ease should growth disappoint. .
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.